91 related articles for article (PubMed ID: 2468926)
21. High selectivity for inhibition of phosphodiesterase III and positive inotropic effects of MCI-154 in guinea pig myocardium.
Bethke T; Meyer W; Schmitz W; Scholz H; Wenzlaff H; Armah BI; Brückner R; Raap A
J Cardiovasc Pharmacol; 1993 Jun; 21(6):847-55. PubMed ID: 7687707
[TBL] [Abstract][Full Text] [Related]
22. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.
Reeves ML; Leigh BK; England PJ
Biochem J; 1987 Jan; 241(2):535-41. PubMed ID: 3036066
[TBL] [Abstract][Full Text] [Related]
23. Phosphodiesterase inhibition by naloxone augments the inotropic actions of beta-adrenergic stimulation.
Park WK; Chang CH; Chae JE; Kim MH; Cho YL; Ahn DS
Acta Anaesthesiol Scand; 2009 Sep; 53(8):1043-51. PubMed ID: 19572940
[TBL] [Abstract][Full Text] [Related]
24. Molecular basis for the cardiovascular activities of amrinone and AR-L57.
Hayes JS; Bowling N; Boder GB; Kauffman R
J Pharmacol Exp Ther; 1984 Jul; 230(1):124-32. PubMed ID: 6086873
[TBL] [Abstract][Full Text] [Related]
25. Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts.
Bethke T; Eschenhagen T; Klimkiewicz A; Kohl C; von der Leyen H; Mehl H; Mende U; Meyer W; Neumann J; Rosswag S
Arzneimittelforschung; 1992 Apr; 42(4):437-45. PubMed ID: 1386515
[TBL] [Abstract][Full Text] [Related]
26. Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle.
Barnette MS; Manning CD; Price WJ; Barone FC
J Pharmacol Exp Ther; 1993 Feb; 264(2):801-12. PubMed ID: 7679736
[TBL] [Abstract][Full Text] [Related]
27. Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition.
Kaheinen P; Pollesello P; Hertelendi Z; Borbély A; Szilágyi S; Nissinen E; Haikala H; Papp Z
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):74-8. PubMed ID: 16433895
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological properties of the positive inotropic and alpha 1-adrenoceptor blocking agent saterinone.
Armah BI; Hofferber E; Stenzel W
Arzneimittelforschung; 1988 Sep; 38(9):1287-92. PubMed ID: 2906245
[TBL] [Abstract][Full Text] [Related]
29. Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs.
Harrison SA; Chang ML; Beavo JA
Circulation; 1986 Mar; 73(3 Pt 2):III109-16. PubMed ID: 3002661
[TBL] [Abstract][Full Text] [Related]
30. Cardiac cGMP-stimulated cyclic nucleotide phosphodiesterases: effects of cGMP analogues and drugs.
Komas N; Le Bec A; Stoclet JC; Lugnier C
Eur J Pharmacol; 1991 Jan; 206(1):5-13. PubMed ID: 1648496
[TBL] [Abstract][Full Text] [Related]
31. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
[TBL] [Abstract][Full Text] [Related]
32. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
33. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs.
Harrison SA; Reifsnyder DH; Gallis B; Cadd GG; Beavo JA
Mol Pharmacol; 1986 May; 29(5):506-14. PubMed ID: 3010079
[TBL] [Abstract][Full Text] [Related]
34. Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats.
Osadchii O; Norton G; Woodiwiss A
Eur J Pharmacol; 2005 May; 514(2-3):201-8. PubMed ID: 15910807
[TBL] [Abstract][Full Text] [Related]
35. Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activity.
Sircar I; Weishaar RE; Kobylarz D; Moos WH; Bristol JA
J Med Chem; 1987 Nov; 30(11):1955-62. PubMed ID: 2822926
[TBL] [Abstract][Full Text] [Related]
36. The inotropic effects of amrinone and milrinone on neonatal and young canine cardiac muscle.
Binah O; Sodowick B; Vulliemoz Y; Danilo P; Rosen M
Circulation; 1986 Mar; 73(3 Pt 2):III46-51. PubMed ID: 3002663
[TBL] [Abstract][Full Text] [Related]
37. Effect of milrinone on ethanol and halothane induced cardiodepression.
Neira S; Penna M
Acta Physiol Pharmacol Latinoam; 1988; 38(2):193-211. PubMed ID: 2847492
[TBL] [Abstract][Full Text] [Related]
38. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4).
Bivalacqua TJ; Champion HC; Rajasekaran M; Sikka SC; Kadowitz PJ; Doherty PC; Hellstrom WJ
J Urol; 1999 Nov; 162(5):1848-55. PubMed ID: 10524946
[TBL] [Abstract][Full Text] [Related]
39. Actions of the novel vasodilator, flosequinan, in isolated ventricular cardiomyocytes.
Kelso EJ; McDermott BJ; Silke B
J Cardiovasc Pharmacol; 1995 Mar; 25(3):376-86. PubMed ID: 7769801
[TBL] [Abstract][Full Text] [Related]
40. Enhanced relaxation and reduced positive inotropic effects of amrinone in ventricular muscle from cats with subacute heart failure. Implications for drug therapy.
Bassett AL; Gaide MS; Lodge NJ; Cameron JS
Adv Myocardiol; 1985; 6():629-36. PubMed ID: 2986264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
